A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, 18-75 years of age;
type 2 diabetes receiving metformin and/or pioglitazone or rosiglitazone for at least 12 weeks;
HbA1c \>=7.0% and \<=10% at screening;
BMI \>=25kg/m2 (\>23kg/m2 for Asians) and \<=45kg/m2 at screening;
stable weight +/- 5% for at least 12 weeks prior to screening.
You may not be if
history of type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes;
history of acute metabolic diabetic complications within the previous 6 months;
evidence of clinically significant diabetic complications;
known proliferative diabetic retinopathy;
myocardial infarction (MI), coronary artery bypass surgery, post-transplantation cardiomyopathy (PTCM) or stroke within the past 6 months;
any abnormality in clinical laboratory test or ECG, which precludes safe involvement in the study as judged by the investigator;
known hemoglobinopathy or chronic anemia;
clinically significant gastrointestinal disease.
Clareo Health | A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
